Skip to main content
SAMIL PHARMACEUTICAL CO.,LTD logo

SAMIL PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000520 ISIN · KR7000520007 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2019-11-12 Capital/Financing Update
Country KR South Korea
Listing KO 000520

About SAMIL PHARMACEUTICAL CO.,LTD

https://www.samil-pharm.com/main/EN

Samil Pharmaceutical Co., Ltd. is a company engaged in the research, development, and manufacturing of pharmaceutical products. The company specializes in ophthalmology and also produces a diverse portfolio of drugs for other therapeutic areas, including the central nervous system (CNS), hepatic conditions, and gastrointestinal disorders. Its product range encompasses prescription medicines as well as over-the-counter remedies for common ailments like fever and colds. In addition to developing its own products, Samil Pharmaceutical offers Contract Development and Manufacturing Organization (CDMO) services to global partners. The company emphasizes research and development and collaborates with other leading pharmaceutical firms.

Recent filings

Filing Released Lang Actions
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from Samil Pharmaceutical regarding the adjustment of the exchange price for its 17th series of exchangeable bonds due to a decline in stock price. This type of disclosure, which details changes to the terms of financial instruments (specifically conversion/exchange prices), falls under capital structure changes. According to the provided definitions, 'CAP' (Capital/Financing Update) is the most appropriate category for updates on financing activities and capital structure changes.
2019-11-12 Korean
투자판단관련주요경영사항(Galmed사 Aramchol 임상 3/4상 개시 발표)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Major Management Matter' (투자판단 관련 주요경영사항) for Samil Pharmaceutical. It announces the commencement of a Phase 3/4 clinical trial by their partner, Galmed. Since it is a specific regulatory announcement regarding business operations/clinical trials that does not fit into financial reporting, dividend notices, or other specific categories, it is classified as a general regulatory filing.
2019-09-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This is a standard regulatory filing used to disclose insider trading or changes in share ownership by company directors or major shareholders. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2019-08-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서). This is a standard regulatory filing in South Korea (DART system) used to disclose insider trading or changes in share ownership by company directors and major shareholders. Based on the provided categories, this fits the 'Director's Dealing' (DIRS) classification, which covers personal share transactions by company directors and executives.
2019-08-22 Korean
최대주주등소유주식변동신고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for Samil Pharmaceutical. It details specific changes in share ownership for individuals classified as major shareholders or related parties, including transaction dates, share counts, and relationships to the company. This falls under the category of Director's Dealing (DIRS) as it reports insider/major shareholder transactions.
2019-08-19 Korean
반기보고서 (2019.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for Samil Pharmaceutical Co., Ltd. for the period ending June 30, 2019. It contains detailed financial statements, business operations, management discussion, and governance information, which fits the definition of an Interim/Quarterly Report (IR). H1 2019
2019-08-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.